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Abstract
Approximately 30,000 cases of non-Hodgkin lymphoma (NHL) occur in the equatorial belt of 
Africa each year. Apart from the fact that Burkitt lymphoma (BL) is very common among children 
and adolescents in Africa and that an epidemic of human immunodeficiency virus (HIV) infection 
is currently ongoing in this part of the world, very little is known about lymphomas in Africa. This 
review provides information regarding the current infrastructure for diagnostics in sub-Saharan 
Africa. The results on the diagnostic accuracy and on the distribution of different lymphoma 
subsets in sub-Saharan Africa were based on a review undertaken by a team of lymphoma experts 
on159 fine needle aspirationsamples and 467 histological samples during their visit to the African 
centres is presented. Among children (<18 years of age), BL accounted for 82% of all NHL, and 
among adults, diffuse large B-cell lymphoma accounted for 55% of all NHLs. Among adults, 
various lymphomas other than BL, including T-cell lymphomas, were encountered. The review 
also discusses the current strategies of the International Network of Cancer Treatment and 
Research on improving the diagnostic standards and management of lymphoma patients and in 
acquiring reliable clinical and pathology data in sub-Saharan Africa for fostering high-quality 
translational research.
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Introduction
Although accurate estimates are difficult, given the paucity of information, it is likely that 
approximately 30,000 cases of non-Hodgkin lymphoma (NHL) occur in the equatorial belt 
of Africa each year and these tumours are among the top ten causes of cancer in this 
geographical region. The fraction associated with acquired immunodeficiency syndrome 
(AIDS) is not available, but may be as high as 50%, although it appears to vary markedly 
throughout the region and is different among children and adults. The incidence of NHL 
since the AIDS epidemic has increased by 2- to 3-fold in some countries, and as much as 13-
fold in others (Kaaya et al, 2006; Otieno et al, 2001; Orem et al, 2004). A realistic estimate 
of the incidence of Burkitt Lymphoma (BL) is 30-70 per million children in equatorial 
African countries. Apart from BL, the incidence for other lymphoma subtypes in equatorial 
Africa remains unknown.
Meaningful research on lymphomas in African cannot be conducted without accurate 
diagnosis. Unfortunately, striking differences still exist with respect to the reliability of 
lymphoma diagnosis between developed and developing countries, due partly to the limited 
number of haematopathologists and partly to the lack of special reagents, such as 
monoclonal antibodies and molecular probes that are indispensable to an accurate diagnosis 
based on the World Health Organization (WHO) classification of haematopoietic and 
lymphoid tissues (Swerdlow et al, 2008).
Unfortunately, the resource limitations (human and material) in Africa severely restrict the 
ability to make an accurate diagnosis early in the disease course and provide adequate 
treatment and follow-up for patients, thus fostering a belief that therapy is pointless. 
However, with improved education and relatively simple augmentation of resources, quite 
simple chemotherapy regimens that require less supportive care are, in fact, feasible in at 
least major centres in Africa. Under the guidance of the International Network for Cancer 
Treatment and Research (INCTR) (http://www.inctr.org/), many of the African centres are 
currently treating lymphomas successfully with protocols specifically designed for the 
prevailing infrastructure in these centres.
The INCTR team has been working in collaboration with many African partners to achieve:
1. Improvements in the speed and accuracy of diagnosis in Africa.
2. Organization of advanced training of pathologists and technicians from the African 
centres.
3. Introduction of standard therapy, adapted to the African setting.
4. Developing translational research studies partnering African and European 
institutions.
To achieve these objectives, the authors, comprising a group of pathologists (along with 
oncologists), have visited several African centres in teams to assess the infrastructure, audit 
the diagnoses offered by the African investigators, introduce capacity building measures, 
provide logistic support for telemedicine and assist with treatment protocols specifically 
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designed for the African setting. As a follow up, the group has conducted annual educational 
meetings in Europe attended by African investigators, European partners and other delegates 
from across the world. Meetings have been held in Italy (Siena – May 2010) and France 
(Paris – May 2011).
This review will focus on a) the current infrastructure for diagnostics in sub-Saharan Africa, 
b) the current diagnostic accuracy in the African setting, c) the distribution of different 
lymphoma subsets in institutions visited in sub-Saharan Africa, d) how diagnostic standards 
can be improved, e) management strategies for lymphoma patients that are likely to yield the 
best outcomes in sub-Saharan Africa, f) preliminary results of the INCTR-assisted treatment 
protocols in sub-Saharan Africa, g) acquisition of reliable clinical and pathology data in sub-
Saharan Africa, and h) strategies to foster high-quality translational research.
Infrastructure for diagnostics in sub-Saharan Africa
During our visits, the infrastructure was found to be highly variable both in terms of 
equipment and available personnel. The annual biopsy numbers varied between 1500 to 
around 16000 among the cellular pathology departments visited. In addition, some of the 
departments had a substantial cytology load, in one instance recording a volume of about 
5000 cases annually. Fine needle aspiration cytology (FNAC) was widely utilized. The 
availability of equipment was heterogeneous. Histokinettes for tissue/biopsy processing, 
rotatory microtome for preparing histology slides, and autostainers were available in some 
centres (especially those that had collaborations with institutions in developed countries). 
Some of these also had facilities for cytospin preparations (especially for cerebrospinal 
fluid) and for preparation of cell-blocks. In some centres, biopsies/tissue samples were 
processed manually. Formalin was used as the tissue fixative in all the places visited. 
Haematoxylin & Eosin (H&E) for histology preparation and H&E, Papanicolaou and May 
Grünwald Giemsa stains for cytology samples were routinely used. In addition, some centres 
were proficient in other histochemical stains that included Periodic acid Schiff, Grocott's 
Gordon & Sweet (reticulin), Perl's Prussian blue (iron), Masson Trichrome, Ziehl Neelsen 
(acid fast bacilli), Masson Fontana, Alcian blue, Mucicarmine, Congo red, Periodic acid 
methenamine silver and Phosphotungstic acid haematoxylin. Turnaround time (TAT) for 
histology depended on infrastructural capacity. Among centres with well-established 
infrastructure, the TAT was less than a week, whereas it was substantially longer in centres 
with suboptimal capacity.
The quality of histology and cytology preparations was variable. In most centres, the 
standard was lower than what would be considered optimal in developed countries. 
However, there were exceptions, where the quality of the H&E stained tissue sections were 
comparable to the best centres in the world. The suboptimal quality of the material could be 
attributed to poor fixation (over/under fixation or improperly prepared fixatives), suboptimal 
tissue processing or suboptimal quality of tissue sectioning. Most of the centres had 
adequate microscopes. The number of pathologists for the work-load was adequate, although 
this should not be taken to apply at a national level - the number of available pathologists in 
Tanzania was reported to be extremely low, and the country lacked pathology trainees. 
Pathologists in training within the universities of Nairobi (Kenya) and Nigeria were highly 
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motivated. Recent pathology textbooks and journals were not available in most centres. 
Despite these drawbacks, pathologists were reasonably well informed.
Although a proportion of the pathologists in sub-Saharan Africa had exposure to centres 
abroad, the laboratory technical staff had not been trained at centres of excellence. Apart 
from one privately-funded hospital, all other centres lacked facilities for 
immunohistochemistry. All local pathologists acknowledged that the lack of 
immunohistochemistry severely hampered their ability to diagnose and classify lymphoid 
proliferations accurately.
Diagnostic accuracy in the African setting
A panel of lymphoma experts (varied between 3-5 among different centres) reviewed 159 
FNA samples and 467 histological samples during the team's visit to the African centres. 
The review process was as follows:
Independent review by the experts
Each expert was provided with a microscope and writing material to record their diagnostic 
impression in each case.
Consensus evaluation
Responses from each of the experts was analysed for consensus in each case. Consensus 
among two of three, three of four or four of five experts was accepted and recorded as the 
consensus diagnosis. Where a consensus diagnosis was achieved, cases were not further 
discussed, unless there was educational value to the host pathologists and pathologists in 
training. The Remainder of cases were considered discrepant.
Consensus discussion
All discrepant cases and those cases with consensus where the hosts wished to have further 
discussion were examined during a “consensus discussion.” Cases in which there was 
disagreement were re-evaluated by the experts. Following the discussion, consensus was 
achieved by the experts in a proportion of the discrepant cases.
Advice on follow-up investigations for histological samples
Cases with consensus required additional immunohistochemical investigations to conform to 
the criteria essential for classification based on the current WHO recommendations. 
Additional testing required was recorded in each case. In cases where a consensus diagnosis 
was not reached despite discussion, a panel of tests and an algorithm for diagnosis was 
documented on site.
Follow-up investigations for histological samples
Immunohistochemistry, in-situ hybridization (ISH) and fluorescent in-situ hybridization 
(FISH) investigations were undertaken in European institutions under the guidance of 
Professor L. Leoncini, and a final diagnosis was determined according to the decision-
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making algorithm prepared. A few cases required further discussion among the experts 
during the meeting in Sienna (May 2010).
Among the 159 FNA samples where a diagnosis of Burkitt lymphoma (BL) had been 
suggested by the pathologists in sub-Saharan Africa, 76% were confirmed to be BL and in 
an additional 12%, a diagnosis of lymphoma other than BL was suggested. In the remaining 
cases (12%), the opinion of the panel included – non-diagnostic material; malignancy, but 
not lymphoma; no evidence of lymphoma or another malignancy.
Among the 467 histological samples that were submitted by the participant centres as 
diagnostic or highly suggestive of lymphoma, a consensus diagnosis was possible in 393 
samples, which included 364 (78%) cases that were confirmed as lymphoma irrespective of 
the subtype. It was difficult to assess the accuracy of making diagnoses of specific 
lymphoma subtypes, as lymphoma subtyping had not been attempted in many cases partly 
due to the fact that basic immunohistochemistry was not available in most centres. A 
previous study suggested an accuracy of around 75% for the diagnosis of BL in Uganda 
(Ogwang et al, 2011).
Distribution of different lymphoma subsets in sub-Saharan Africa
Cases reviewed
A total of 467 histological specimens were reviewed. This included 132 cases from Lacor 
Hospital, Uganda; 86 cases from Kenyatta National Hospital, Kenya; 79 cases from Aga 
Khan University Hospital, Kenya; 92 cases from Muhimbili National Hospital, Tanzania; 44 
cases from Obafemi Awolowo University, Nigeria; and 34 cases from University College, 
Ibadan, Nigeria. Of these cases, 258 (57%) were males, 192 (43%) were females and the 
gender was not recorded in 17 cases. Age had not been recorded in10 patients. Among the 
rest, 189 (41.4%) patients were children and adolescents (<18 years age). However, Lacor 
Hospital was a paediatric hospital and when this institutions’ cases were excluded, there was 
85/335 (26%) children and adolescents (<18 years age). Among them, the mean and median 
age was 35.9 years and 36 years respectively.
Among the 188 children and adolescent cases (<18 years age), 114 (62%) were males, 70 
(38%) were females and the gender was not recorded in 4 cases. Among the 267 adult cases, 
140 (53.5%) were males, 121 (46.5%) were females and the gender was not recorded in 6 
cases.
Diagnosis
Among the 467 cases, the panel found 393 cases to be assessable. This included 312 cases of 
non-Hodgkin lymphoma (NHL) and 52 cases of Hodgkin lymphoma (HL). 11 cases were 
classified as benign lymph node lesions and 18 cases were confirmed as malignancies other 
than lymphomas. Among the 188 children and adolescent cases (<18 years age), 160 were 
assessable, of which 132 were diagnosed as NHL and 19 as HL. Among the 267 adult cases, 
172 of 223 assessable cases were considered NHL and 32were diagnosed as HL.
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In children and adolescents (<18 years age), BL accounted for 82% of all NHLs. However, 
other lymphomas such as diffuse large B-cell lymphoma (DLBCL) (7.5%), precursor 
lymphoid neoplasms and anaplastic large cell lymphoma, ALK positive were also recorded. 
Among the 19 HL encountered in children and adolescents (<18 years age), all but one case 
were classical HL (cHL) (Tables 1 & 2).
In adults, DLBCL was the most common NHL, accounting for 55% of all NHLs. However, 
a wide variety of other lymphomas, such as chronic lymphocytic leukaemia / small 
lymphocytic lymphoma (9%), BL (9%), plasmablastic lymphoma (4%), follicular 
lymphoma (FL) (3%) and plasmacytoma (3%) were also noted. Among the 5 cases of FL, 4 
were of grade 1-2 and one case had features of grade 3b. Among DLBCL, 2 represented 
Richter transformation and, one was a cutaneous DLBCL. A component of FL was 
recognized in 9 DLBCLs. The nodular sclerosis subtype of cHL accounted for more than 
one-half of NHL cases (Tables 3 & 4).
Clinicopathological correlations
BL was predominantly a disease in children and adolescents. Even after exclusion of cases 
from the paediatric hospital, among the remaining 42 BL cases, more than 75% occurred in 
the first two decades of life. The median age for BL was 9 years. Among the 122 cases of 
BL where surgical biopsies were evaluated, the male:female ratio was 1:1. The more 
common sites of initial presentation of BL among children were abdomen (24%), jaw 
(24%), ovary (10%), neck lymph nodes (8%), spleen, liver, pelvis and kidney (~5% each). 
The more common sites of initial presentation of BL among adults were ovary (20%), 
parotid and jaw (13% each). It is entirely possible that this distribution pattern was as much 
due to the method of diagnosis chosen (fine needle versus cutting needle or biopsy) as to the 
characteristic distribution pattern of the tumour.
DLBCL was predominantly a disease of adults. After exclusion of cases from the paediatric 
hospital, 92% of the remaining 95 cases occurred in adults. The median age for DLBCL was 
50 years. The male:female ratio was 1.5:1. The more common sites of initial presentation of 
DLBCL in adults were lymph nodes (40%), intestines (8%), stomach (7%), abdomen (7%), 
sinonasal/tonsillar/nasopharyngeal (6%), oral cavity (4%) and breast (3%).
HL was predominantly a disease of childhood and early adulthood. After exclusion of cases 
from the paediatric hospital, nearly 75% of the remaining 50 cases occurred before the age 
of 30 years, with a median age of 22 years. Only 10% of cases occurred after the age of 50 
years. The male:female ratio was 1.2:1. This pattern is likely to be at least in part due to the 
age-structure of the population.
Viral associations
In-situ hybridization for Epstein-Barr virus (EBV) using the EBER-1 probe was attempted 
on the paraffin blocks. However, in a large proportion of cases, RNA preservation was 
suboptimal for definitive documentation. Among the interpretable cases EBV-association 
was documented in 21/27 (78%) of BL, 4/29 (14%) of DLBCL, 6/6 (100%) of plasmablastic 
lymphoma and 6/7 (86%) of cHL. Other EBV-positive lymphomas seen at lower frequencies 
included 2 cases of peripheral T-cell lymphoma, unspecified; 1 case of follicular lymphoma, 
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grade 3b; one case of B-cell lymphoma unclassifiable with features intermediate between 
DLBCL and BL; one case of B-cell lymphoma unclassifiable with features intermediate 
between DLBCL and cHL; and 1 case of NK/T cell lymphoma, nasal type. Documentation 
of HIV association among cases on which histology specimens were reviewed was 
extremely poor. Among them, a positive documentation of HIV-association was noted in 7 
cases of BL, 4 cases of DLBCL, 2 cases of cHL and one case of plasmablastic lymphoma, 
and a negative documentation of HIV association was noted in 12 cases of BL.
Improving diagnostic standards in sub-Saharan Africa
Although in the developed world, the importance of the correct diagnosis is appreciated as a 
critical issue, this is still an evolving concept in some of the developing countries, especially 
in Africa, as observed by members of our group, who have regularly visited East and West 
sub-Saharan African countries for the purposes of reviewing lymphomas for one or more 
studies. In particular, there are striking differences in the TAT for lymphoma diagnosis and 
in the accuracy of diagnosis - differences that have a profound impact on patient outcome. 
The current problems in the practice of lymphoma diagnosis include basing treatment 
decisions on FNAC in a large proportion of cases, poor quality histology in a proportion of 
cases where biopsies are performed, complete lack of immunohistochemistry and other 
supportive investigations, lack of continuing education, and a failure to apply the current 
criteria for diagnosis of various lymphoid malignancies. In Africa, a majority of the 
laboratories still use the Working Formulation for Clinical Usage, a lymphoma classification 
from the early 1980's, which is based on morphology alone and does not include most of the 
entities recognized in the last 20 years. Without accurate diagnosis, neither meaningful 
research projects nor effective patient management can be instituted. Though there are no 
magic answers for an issue of this magnitude, “twinning” or other forms of communication 
for teaching purposes between pathologists in institutions in the developed countries and 
developing countries seems to be the most likely approach to ensuring sustainable 
improvements. Twinning projects focused on lymphomas would help to improve diagnostic 
accuracy through capacity building, consultations and both direct and indirect technology 
transfer.
Therefore, a systematic approach aimed at improving the diagnostic standards through 
partnerships with institutions in African countries in order to bring them closer to the 
standards of practice among their European/North American counterparts would be a helpful 
strategy. This approach would allow the education of collaborating African pathologists 
with respect to the more recent concepts of lymphoma classification and diagnosis, while 
introducing essential tools to modern diagnosis such as immunohistochemistry, molecular 
cytogenetics and other molecular tools. Building local capacity to initiate 
immunohistochemistry with a limited panel of immunostains would be critical for improving 
diagnostic standards.
Tele-pathology, through capturing of still-images and their online submission for discussion 
with experts in the field, is yet another strategy that might lead to improvements in 
diagnosis. This has been popularized by one of the co-authors (Dr. Nina Hurwitz) whose 
inputs into the development of the web-based case discussion site iPath hosted through the 
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INCTR (http://www.ipath-network.com/inctr/) have been tremendous. The facility has had 
an immense appeal in sub-Saharan Africa, as the provision of a microscope with digital 
camera attachment to capture still images is fairly inexpensive. Most of the African centres 
we visited have reasonably good internet facilities that enable them to post images online. 
The success of this strategy is highly dependent on quality of the histology/cytology 
preparations and the onsite pathologist's ability to adequately capture the diagnostic and the 
problematic areas on the slide. The dialogue and the discussion following the submission of 
images are intended to improve the overall diagnostic standards. Lack of 
immunohistochemistry support on lymphomas requiring immunohistochemistry could 
restrict the experts in making a specific and definitive diagnosis on these submissions.
Strategies for management of lymphoma patients in sub-Saharan Africa
Burkitt lymphoma
The clinical syndrome of BL was first recognized in Ugandan children (Burkitt, 1958) and 
proved to be an important model tumour because it was the first human tumour to be 
associated with a virus (EBV) and with another common infection in equatorial Africa - 
malaria. Another important lesson learnt in the pioneering days of chemotherapy was that 
BL is highly sensitive to, and indeed, curable, by chemotherapy alone (Magrath, 2009). This 
is fortunate, given that the vast majority of tumours are inoperable at presentation, and 
surgery may never be curative, while radiotherapy was then and remains extremely limited 
in availability, although, like surgery, is of limited value in the treatment of BL. It is 
particularly sad, therefore, that the survival rate of this tumour in equatorial Africa – now 
over 90% overall in children in Europe, remains very low and not even measurable – even in 
major centres where this would be possible, the quality of the data collected generally 
prevents an estimate of the survival rate. A study conducted in Africa in the early 1970's, 
although not completed, suggested that a simultaneous rather than sequential combination of 
active drugs, consisting of cyclophosphamide, vincristine and methotrexate (COM) would 
be more effective at controlling systemic disease (Olweny et al 1980), although at the time, 
effective central nervous system (CNS) prophylaxis had not been developed and a number 
of isolated CNS relapses were observed. The efficacy of COM in conjunction with effective 
CNS prophylaxis has never been tested in the African setting because of resource 
limitations, lack of training in the conduct of clinical trials, abandonment of therapy and 
poor follow-up. However, a high fraction of major African centres still use a variant of 
COM therapy. Thus, in spite of the considerable amount of time that has passed since the 
original study, these results provide a reasonable starting point for the present stepwise 
approach to the development of BL therapy that is feasible in an African setting where 
trained oncologists are few or absent, supportive care is limited and a fraction of patients 
(varying with age) will also have AIDS. In contrast, intensive chemotherapy of the kind 
used in Europe is not feasible for reasons of cost, complexity of treatment, and the need for 
excellent supportive care and management by experienced oncologists, which is currently 
not available in Africa.
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Diffuse Large B Cell Lymphoma and AIDS-associated NHLs
A similar situation pertains with respect to DLBCL, where if any therapy can be called 
standard in Africa, it is CHOP (cyclophosphamide, hydroxyrubicin, vincristine and 
prednisone). Many patients in Africa do not receive the full complement of drugs, possibly 
because hydroxyrubicin is relatively expensive. Limited information is available with 
respect to the treatment of DLBCL in Africa. However, recent data has suggested that in 
children and young adult patients up to the age of 30-35, the predominant DLBCL subtype 
is the germinal centre cell type (Oschlies et al, 2006), which has a better prognosis. Indeed 
in one large population-based study, over a third of children diagnosed with DLBCL had a 
molecular profile of BL (Klapper et al, 2008). No difference in outcome between 
histologically diagnosed DLBCL and BL when treated with BL therapy has been 
demonstrated in this young age group in Europe. In a recent study from Uganda, BL 
comprised approximately one quarter of all NHL, a high fraction of the remainder were 
DLBCL and the majority of patients were less than 20 years of age (Mwakigonja et al. 2008, 
Oriol et al, 2008). Thus, for most patients, even with DLBCL, BL therapy may well be a 
reasonable and feasible approach for a high fraction of patients; this could have the 
advantage of avoiding the use of the more expensive and potentially toxic hyroxyrubicin 
without compromising results.
Preliminary results of the INCTR-assisted treatment protocols in sub-
Saharan Africa
For the reasons provided above, the INCTR BL strategy group opted to conduct a pilot study 
using a standardized version of COM as first-line therapy in a simple clinical trial for 
previously untreated BL. Guidelines for the safe administration of therapy and the provision 
of supportive care were included in the protocol, and cytotoxic drugs and antibiotics were 
provided free-of-charge, in addition to salaries and training for local persons to collect 
accurate data and follow-up of patients who failed to return for appointments after 
completion of therapy. Patients who developed progressive tumour at any time in their 
treatment (i.e., during remission induction or after achieving a complete remission) were 
treated with a second combination regimen, also felt likely to be feasible in the African 
setting, consisting of ifosfamide, mesna and cytosine arabinoside. To date, over 460 patients, 
nearly all children, with BL (including the few associated with HIV infection) have been 
treated since 2004 in centres in Kenya, Tanzania and Nigeria. High remission rates have 
been achieved with front line therapy, and excellent survival rates for the African context 
obtained in some centres, although significant variability in survival rates was observed 
among different centres – most probably due to failure to complete therapy, or to be treated 
with second-line therapy (which was shown to be active) in the presence of progressive 
disease in centres with a worse outcome.
Importantly, in addition to markedly improved outcome of treatment compared to patients 
treated prior to initiation of the study, follow up and documentation of results have all been 
greatly improved. Moreover, the identification of avoidable deaths and the proven efficacy 
of the second-line regimen suggest that this result can be improved upon in the coming years 
and the benefits extended to additional patients in the same or other African countries.
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Acquiring reliable clinical and pathology data in sub-Saharan Africa
Laboratory studies require patient tissues and/or fluids, which must be correctly collected, 
stored and documented in order that correct results may be obtained and, where appropriate, 
correlations made with clinical findings, such that accurate evidence is collected. The 
INCTRs strategy for serum and tissue collection is as follows:
Serum samples
Ideally, serum samples (from 7-10 ml of blood) should be obtained on at least two 
occasions: one immediately prior to treatment (ideally, on the day that treatment begins, but 
at least within 72 h prior to the initiation of treatment) and the other immediately before 
cycle 2 (within 72 h prior to the initiation of the cycle. Ideally, serum should be stored in 
one 2 ml aliquot and the remainder in 1 ml aliquots (3 vials per patient). Each vial should be 
labelled with the patient study number (which should be a unique identifier) and date. The 
label on the tube should be firmly attached, or if more convenient, an indelible marker pen 
or a pen used for writing on glass should be used. Vials should then be placed in a 
sequentially numbered serum storage box with standard compartments of a size to hold the 
serum vials firmly. All boxes should be kept at −80C. Precautions should be taken against 
thawing, and the freezer should be connected to an emergency generator that automatically 
switches on in the event of a power failure.
Tissue samples
An attempt to obtain tumour/lymph node samples should be made in every case. Diagnosis 
rendered on FNA has limitations, and using only FNA for diagnosis can compromise at the 
specific diagnosis and impact on correct treatment. Errors in FNA diagnosis can be difficult 
to resolve even during a review undertaken later by a specialist haematopathologist. If an 
open or a surgical biopsy is not possible, a needle core biopsy should be attempted. An 
imprint of the needle core biopsy or the open biopsy can be used for immediate diagnosis, 
on which treatment can be based and initiated. Diagnosis rendered on imprint cytology 
should be followed by a more formal diagnosis on histology possibly supported by 
immunohistochemistry. Informed consent should be sought from the patients or their 
guardians regarding the performance of the procedure prior to obtaining consent for 
participation in the treatment protocol.
Appropriate handling of tissue samples is critical for correct diagnosis and reliable research. 
Once the imprints have been obtained, the remainder of the material should arrive at the 
pathology service within 30 min of being surgically removed. The tissue should be sectioned 
by a pathologist into 3 mm slices for obtaining ‘touch preparations’ or ‘imprints’. At least 
two touch preparations should be obtained - one imprint should be air-dried and stained with 
May-Grunwald-Giemsa, and the other fixed with cytofix and stained with Papanicolaou. 
Tissue slices should then be fixed in 10% buffered formalin at the optimal fixation time of 
24 h at room temperature. If the lymph node is large enough, additional slices should be 
prepared for cryopreservation. Labelling of frozen samples should be performed similar to 
those described for serum, although larger vials and boxes will be required, and frozen 
samples should be stored in a different part of the freezer than serum samples.
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Records on storage of frozen serum and tissue samples and on the paraffin block archives 
should be maintained on an electronic data base so that data is readily available and 
searchable, as well as analysable.
Data Management
Robust electronic database recording clinical and pathological information is critical for 
translational research. The INCTR has a purpose-built database that has been installed in all 
its participating centres. It overcomes problems of intermittent internet connection in Africa 
because data is entered off-line, then uploaded and synchronized with the central database in 
Brussels as data entry for individual patients is completed. This both increases the security 
of data storage (because it is now centralized on a secure server) and enables data to be 
examined immediately and any necessary queries generated without delay, as local site data 
is synchronized with the data kept on the central server immediately it has been entered at 
the site level. It also avoids use of e-mail for data transfer with its associated delays and 
hazards. The database records all the essential patient presentation data, clinical findings and 
results of pathological and imaging investigations. Data regarding treatment and follow-up 
is also appended periodically as per standard practices determined by INCTR's Clinical 
Trials Office.
Fostering high-quality translational research
A respectful partnership between investigators in Africa and developed countries can indeed 
result in high-quality translational research and the establishment of research infrastructure 
in Africa working partnership. Within our group, Professor Leoncini and his associates have 
been able to establish this. Studies from this group have led to: 1) Identification of 
differences between endemic BL and sporadic BL in terms of the differences in the 
immunoglobulin gene mutation-rates and the possible role of antigen selection (Bellan et al, 
2005); 2) Identification of the role of RBL2 gene in endemic BL and the target genes of 
RBL2/p130 (De Falco et al, 2007); 3) Identification of alternate pathogenetic mechanisms 
involving microRNA in MYC translocation-negative BL (Leucci et al, 2008); and 4) several 
studies on gene and microRNA expression in BL (Leucci et al, 2010; Onnis et al, 2010; 
Piccaluga et al, 2011). It should be noted that microRNA studies and studies requiring 
immunohistochemistry, ISH or FISH can be performed on formalin-fixed tissue samples.
Though the opportunities for high-quality research through collaboration with centres in 
Africa is huge, investments into improving diagnostic accuracy and infrastructure, and 
optimal patient management while maintaining a good clinical and pathology database, are 
of paramount importance.
Conclusion
The discovery of BL in Africa has led us to extraordinary achievements in oncology, 
medicine, epidemiology and science. Half a century after this discovery, treating African 
patients with BL remains a challenge. The study of African lymphomas is likely to lead us to 
new discoveries. However, these ventures require robust partnerships between Africa and 
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the rest of the world. Improving the infrastructure for accurate diagnosis and optimal patient 
management are key to meaningful translational research and scientific advances.
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Table 1
Lymphoma subtype among 132 paediatric and adolescent (<18 years) NHL cases
Precursor lymphoid neoplasms 4 (3%)
    B lymphoblastic leukaemia/lymphoma 1 (0.7%)
    T lymphoblastic leukaemia/lymphoma 1 (0.7%)
    Blastic leukaemia/lymphoma, not otherwise specified 2 (1.5%)
Mature B-cell neoplasms 123 (92.5%)
    Diffuse large B-cell lymphoma (DLBCL) 10 (7.5%)
    Burkitt lymphoma (BL) 109 (82%)
    B-cell lymphoma, unclassifiable with features intermediate between DLBCL & BL 4 (3%)
Mature T-cell & NK cell neoplasms 3 (2.2%)
    Peripheral T-cell lymphoma, not otherwise specified 1 (0.7%)
    Anaplastic large cell lymphoma, ALK positive 2 (1.5%)
NHL, not further classifiable due to technical reasons 2
DLBCL, diffuse large B-cell lymphoma ; BL, Burkitt lymphoma
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Table 2
Histological subtypes among 19 paediatric and adolescent (<18 years) HL cases
Nodular lymphocyte predominant Hodgkin lymphoma 1 (5%)
Nodular sclerosis classical Hodgkin lymphoma 7 (37%)
Mixed cellularity classical Hodgkin lymphoma 7 (37%)
Lymphocyte-depleted classical Hodgkin lymphoma 4 (21%)
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Table 3
Lymphoma subtype among 172 adult NHL cases
Precursor lymphoid neoplasms 8 (4.7%)
B lymphoblastic leukaemia/lymphoma 1 (0.6%)
T lymphoblastic leukaemia/lymphoma 4 (2.4%)
Blastic leukaemia/lymphoma, not otherwise specified 3 (1.8%)
Mature B-cell neoplasms 157 (91.3%)
Chronic lymphocytic leukaemia / small lymphocytic lymphoma 16 (9.4%)
Lymphoplasmacytic lymphoma 1 (0.6%)
Plasmacytoma 5 (3%)
Extranodal marginal zone lymphoma of MALT type 2 (1.2%)
Nodal marginal zone lymphoma 4 (2.4%)
Mantle cell lymphoma 1 (0.6%)
Follicular lymphoma 5 (3%)
Primary cutaneous follicular lymphoma 1 (0.6%)
Diffuse large B-cell lymphoma (DLBCL) 95 (55%)
Plasmablastic lymphoma 6 (3.6%)
Burkitt lymphoma (BL) 15 (9%)
B-cell lymphoma, unclassifiable with features intermediate between DLBCL & BL 5 (3%)
B-cell lymphoma, unclassifiable with features intermediate between DLBCL & classical Hodgkin lymphoma 1 (0.6%)
Mature T-cell & NK cell neoplasms 5 (3%)
Extranodal NK/T cell lymphoma, nasal type 1 (0.6%)
Peripheral T-cell lymphoma, not otherwise specified 3 (1.8%)
Primary cutaneous anaplastic large cell lymphoma 1 (0.6%)
NHL, not further classifiable due to technical reasons 2
DLBCL, diffuse large B-cell lymphoma ; BL, Burkitt lymphoma ; MALT, mucosa-associated lymphoid tissue
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Table 4
Histological subtypes among 32 cases of HL in adults
Nodular lymphocyte predominant Hodgkin lymphoma 3 (9.4%)
Nodular sclerosis classical Hodgkin lymphoma 17 (53%)
Lymphocyte rich classical Hodgkin lymphoma 1 (3%)
Mixed cellularity classical Hodgkin lymphoma 10 (31.2%)
Lymphocyte depleted classical Hodgkin lymphoma 1 (3%)
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